Turn Therapeutics Reports GX-03 Skin Inflammation Research
Westlake Village, California, August 20, 2026 Turn Therapeutics announced new peer-reviewed research providing in-vivo evidence that GX-03 selectively reduces...
IL-31
Advertisement
Bambusa Therapeutics Reports Positive Early Phase 1 Results for BBT001 in Atopic Dermatitis
BOSTON, July 27, 2026 Bambusa Therapeutics announced encouraging preliminary proof-of-concept results from its ongoing global Phase 1 clinical trial...
Bambusa Therapeutics Completes BBT001 Trial Enrollment
BOSTON, MASSACHUSETTS, April 30, 2026 Bambusa Therapeutics has announced the successful completion of patient enrollment in its Phase 1b/2a...
Advertisement
